A Revolutionary, Non-Toxic and Effective New Approach to Cancer Treatment
Frank Arguello, MD
  • Have you, or someone you love, been recently diagnosed with cancer?
  • Do you have a recent recurrence of your cancer?
  • Do you have metastatic (Stage IV) cancer?
  • Are you under conventional chemotherapy and your disease continues progressing?
If you have answered "yes" to any of the above questions, please continue reading. The information on this website and video could be the turning point you have been looking for in your life.

Director, Atavistic Chemotherapy Clinical Trial
Former Assistant Professor of Oncology,
and Pediatrics, Hematology and Oncology,
University of Rochester School of Medicine and Dentistry. Rochester, NY.
Former Senior Scientist, Division of Cancer Treatment & Diagnosis,
National Cancer Institute, National Institutes of Health. Frederick, MD.

Google Scholar


           In Scientific Collaboration with his Brothers.......


J. Rafael Arguello, M.D., Ph.D.                               Gerardo R. Arguello, Ph.D.
         Molecular Immunobiology                                          Virology & Plant Genetics         
    PhD, University College of London                             PDF, North Carolina State University

Google Scholar                                                        Google Scholar


This work is dedicated to the loving memory of our mother.....

Celia Astorga de Arguello
(1932 - 1982)
If only the love of your young children could have saved you,
you certainly would not have died. But our love and tears were not enough.
Let's hope the work derived from these concepts
prevent other families from experiencing the pain and sorrows
that we went through with your premature death.

Important: This clinical study is registered with the National Institutes of Health (USA) under the identifier: NCT02366884 ( This study was initiated in 2011 by Dr. Frank Arguello by his own initiative, all in an effort to find a better understanding and more effective treatments for patients with cancer.  This is purely a scientific and academic endevour, NOT being sponsored by any pharmaceutical company. It has been financed and sponsored in its entirety by the Arguello brothers. This is a not-for-profit activity, and patients pay only for the cost of the drugs involved in their treatment and services ($1,500 USD/month) when they can afford to do so. Participating patients have been from the U.S. or Canada. About 70 percent of patients have been treated for free or for a nominal charge since they came from countries with smaller economies (Mexico, Greece, etc.).